SCHEMBL21749010

SCHEMBL21749010

CC(C)(COc1cccc(F)c1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.56
DGAT1 O75907 3/20 0.52
MRGPRX4 Q96LA9 1/20 0.47
NR4A2 P43354 1/20 0.47
CYP2C9 P11712 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
MAOB P27338 1/20 0.46
CYSLTR2 Q9NS75 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
MAP4K4 O95819 1/20 0.45
AR P10275 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
EGLN2 Q96KS0 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30783154 1.00 SSTR4 (0.56) SSTR4DGAT1MRGPRX4NR4A2CYP2C9
SCHEMBL5724626 0.81 PPARA (0.58) SSTR4DGAT1CYP2C9MAP4K4PPARG
SCHEMBL21748731 0.80 DGAT1 (0.52) SSTR4DGAT1NR4A2CYP2C9MAOB
SCHEMBL12250983 0.80 MAOB (0.47) SSTR4MRGPRX4MAOBAR
SCHEMBL5153039 0.78 MRGPRX4 (0.50) DGAT1MRGPRX4NR4A2CYP2C9ALDH1A1
SCHEMBL4037965 0.77 CYP2C9 (0.52) DGAT1MRGPRX4CYP2C9MAP4K4
SCHEMBL24440181 0.76 PPARA (0.61) PPARGPPARA
SCHEMBL3373353 0.76 PPARA (0.54) CYP2C9MEN1ALDH1A1KMT2AMAP4K4
SCHEMBL1431527 0.75 LMNA (0.64) MRGPRX4NR4A2MEN1ALDH1A1HPGD
SCHEMBL21991305 0.75 DGAT1 (0.49) DGAT1MRGPRX4CYP2C9MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 US disclosed
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 CN disclosed
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-26 US disclosed
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-29 US disclosed
CN-112236423-A Piperidinyl-3- (aryloxy) propanamides and propionates 武田药品工业株式会社 2021-01-15 CN disclosed
EP-3759094-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES Takeda Pharmaceutical Company Limited (JP) 2021-01-06 EP disclosed
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11045457-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R SSTR4 1/4885DGAT1 4831/4885MRGPRX4 34/4885
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R SSTR4 1/4885DGAT1 4831/4885MRGPRX4 34/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R SSTR4 1/4885DGAT1 4831/4885MRGPRX4 34/4885
US-20200061041-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R SSTR4 1/4885DGAT1 4831/4885MRGPRX4 34/4885
US-20230021834-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R SSTR4 1/4885DGAT1 4831/4885MRGPRX4 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.